No Data
Express News | Myriad Genetics Inc : Stephens Raises Target Price to $30 From $25
Myriad Genetics (NASDAQ:MYGN) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only
What We Don't Know Can Hurt: New Cancer Risk Survey From Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Express News | Myriad Genetics Inc : TD Cowen Raises Target Price to $28 From $23
Express News | Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
TrytosaveabitOP Jaguar8: Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 TrytosaveabitOP: What volume do you usually set like 1M?
TrytosaveabitOP Jaguar8: 300K in 3 minutes
Jaguar8 TrytosaveabitOP: Wow that is fast volume
View more comments...